<DOCUMENT>
<TYPE>EX-10.6.1
<SEQUENCE>17
<FILENAME>d857371dex1061.htm
<DESCRIPTION>EX-10.6.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
  
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.&#151;CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>U<SMALL>NIVERSITY</SMALL> <SMALL>OF</SMALL> M<SMALL>INNESOTA</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT TO THE EXCLUSIVE PATENT LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS FIRST AMENDMENT TO THE EXCLUSIVE PATENT LICENSE AGREEMENT</B> (the &#147;First Amendment&#148;) is entered into as of the date of last
signature by and between the Regents of the University of Minnesota, a Minnesota constitutional corporation under the laws of the state of Minnesota, having a place of business at 1000 Westgate Drive, Suite 160, St. Paul, MN 55114 (the
&#147;University&#148;), and Cellectis S.A., a corporation under the laws of the country of France having a business address of 8, rue de la Croix Jarry, 75013, Paris, France (the &#147;Licensee&#148; or &#147;Cellectis S.A.&#148;).<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The University and the Licensee are individually referred to herein as a &#147;Party&#148; or collectively as the &#147;Parties&#148;. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BACKGROUND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">University
and Licensee entered into an Exclusive Patent License Agreement, dated and effective as of 10&nbsp;January 2011, (the &#147;License Agreement&#148;), which incorporated the Terms and Conditions as defined in the License Agreement under which
University granted to Licensee an exclusive license to University&#146;s rights in the Licensed Technology, as defined in the License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties now wish to amend and clarify the Licensees&#146; rights and obligations under the License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, the Parties agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD> 
<TD ALIGN="left" VALIGN="top"><B>Definitions</B>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms used in this First Amendment that are not otherwise defined herein shall
have the meanings ascribed to them in the Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD> 
<TD ALIGN="left" VALIGN="top"><B>Amendments to the Agreement</B>. Effective the First Amendment Effective Date, the Parties hereby agree to amend the License Agreement as follows: </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Licensee</U>. Section&nbsp;1 of the EPLA is hereby amended to add the following provision: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;For any avoidance of doubt, an Affiliate of Cellectis S.A. shall not be considered a Third Party.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Definitions</U>. The Terms and Conditions are hereby amended to add the following provisions as sections 1.19, 1.20 and 1.21: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;1.19 TALEN(s)&#146; shall mean a Licensed Product that is an endonuclease whose DNA recognition domain is composed of DNA binding domains
derived from transcription activator-like (TAL) effectors protein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;1.20 [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;1.21 Cellectis Bioresearch&#146; shall mean Cellectis Bioresearch SAS, which is an Affiliate of Cellectis S.A.&#148; </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION. </B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Sublicense Revenues</U>. Section&nbsp;1.14 of the Terms and Conditions are hereby deleted
in its entirety and the following substituted in its stead: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;&#145;Sublicense Revenues&#146; means [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Running Royalties</U>. The EPLA is hereby amended to add the following provision to subsection 11.4.1: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;For the avoidance of doubt, the Parties acknowledge and agree that sublicenses granted by the Licensee to a Third Party solely as part of
the Third Party&#146;s purchase of TALEN(s) from Licensee shall be reported as Commercial Sales of Licensed Products under this subsection 11.4.1 on which a [***] royalty as provided in this subsection shall be due. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;For further clarity, for sublicenses granting the Third Party both a license (i)&nbsp;to use Licensed Products for such persons&#146;
commercial or other lawful purposes as part of a purchase of the Licensed Products and (ii)&nbsp;to practice the Licensed Technology to make and use TALEN(s), the Licensee shall clearly and reasonably specify in the sublicense agreement which
payments are linked to the purchase of Licensed Products and which to the right to practice the Licensed Technology to make and use TALEN(s).&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;For additional clarity, such [***] royalty is due on i) the sale of Licensed Products by Licensee (for example, when Licensee sells a
TALEN, or a cells modified with the TALENs); or ii) the sublicense fee associated with sales of Licensed Products (for example, when Licensee sells a TALEN and grants the right to use the TALEN to develop cells).&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Payments</U>. Section&nbsp;11.5 of the EPLA is hereby deleted in its entirety and the following substituted in its stead: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;As determined and payable as provided in section 6.4 of the Terms and Conditions, the licensee shall pay to the University [***] of all
Sublicense Revenues paid to the Licensee in a calendar quarter during the Term and the Post-termination Period within thirty (30)&nbsp;days after the last day of such quarter. Notwithstanding any provision of this Agreement to the contrary, the
Licensee shall have no obligation to pay the University any amount under this section 11.5 for moneys paid by Third Parties to the Licensee in connection with the Licensee granting such persons a right to use Licensed Products for their commercial
or other lawful purposes as part of a purchase of Licensed Products.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>Financial Compensation</U>. The EPLA is hereby amended
to add the following provision as section 11.11: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;1.1.11 In addition to amounts owed by the Licensee to the University under other
sections of this Agreement, the Licensee shall pay the University the following sums: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(i) within sixty (60)&nbsp;days after the final day
of each calendar quarter during the Term and the Post-termination Period, [***] of all moneys actually paid to Cellectis Bioresearch under [***]; provided, however, the Licensee shall have no obligation under this part (i)&nbsp;of section 11.11 to
make such payments for moneys earned after the third (3rd)&nbsp;anniversary of the effective date of [***]; </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[***] CONFIDENTIAL MATERIAL REDACTED
AND SEPARATELY FILED WITH THE COMMISSION. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(ii) within thirty (30)&nbsp;days after the actual receipt by Cellectis Bioresearch of the
milestone payment for having obtained cumulative Net Revenues of at least [***], as provided in [***]; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(iii) within thirty
(30)&nbsp;days after the actual receipt by Cellectis Bioresearch of the milestone payment for having obtained cumulative Net Revenues of [***].&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Patent Application Filings during the Term</U>. The Terms and Conditions are hereby amended to add the following provision as section
4.4: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;4.4 The Licensee, without having obtained the consent of the University, may seek and obtain intellectual property protection
for improvements to the Licensed Technology developed solely by the Licensee or developed jointly by the Licensee and a third party, other than an employee or student of the University working in the course of their employment or academic duties or
using University resources.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 <U>Licensee&#146;s Address</U>. Section&nbsp;12 of the EPLA is hereby deleted in its entirety and
the following substituted in its stead: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Notices will be sent to the Licensee at: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Cellectis S.A. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attn.:
Mr.&nbsp;Andre Choulika (Chief Executive Officer) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">8, rue de la Croix Jerry </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">75013 Paris, FRANCE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Voice Phone
No.: +33 1 81 69 16 00 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile No.: +33 1 81 69 16 06 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 <U>Licensee&#146;s Contact Person for Patent Prosecution Consultation</U>. Section&nbsp;13 of the EPLA is hereby deleted in its entirety
and the following substituted in its stead: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;The University will, as set forth below in this Agreement, communicate with the contact
person named below with respect to patent prosecution and maintenance: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Cellectis S.A. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">8, rue de la Croix Jarry
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">75013 Paris, FRANCE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Voice
Phone No.: +33 1 81 69 16 00 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile No.: +33 1 81 69 16 06 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[***] CONFIDENTIAL MATERIAL
REDACTED AND SEPARATELY FILED WITH THE COMMISSION. </B></P>
 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Upon ten (10)&nbsp;days prior written notice or email to the University, the Licensee may change
the person designated above.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. General Provisions</B>.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 Except as amended in this First Amendment, the terms of the License Agreement remain unchanged and in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 The License Agreement, as amended by this First Amendment, constitutes the entire agreement between the Parties with respect to the
subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 This First Amendment may be executed in two counterparts, each of which will be deemed an original, but all of
which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused their duly
authorized representatives to execute this First Amendment to the Exclusive Patent License Agreement.<B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">

 
<TR> 
<TD WIDTH="4%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="42%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="4%"></TD> 
<TD VALIGN="bottom"></TD> 
<TD WIDTH="4%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="42%"></TD></TR>

 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" COLSPAN="3">Regents of the University of Minnesota</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" COLSPAN="3">Cellectis S.A.</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">By:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jay W. Schrankler</P></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">By:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andr&eacute; Chjoulika</P></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Name:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">Jay W. Schrankler</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">Name:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">Andr&eacute; Chjoulika</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="8"></TD> 
<TD HEIGHT="8" COLSPAN="2"></TD> 
<TD HEIGHT="8" COLSPAN="2"></TD> 
<TD HEIGHT="8" COLSPAN="2"></TD> 
<TD HEIGHT="8" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Title:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">Executive Director</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">Title:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">Chief Executive Officer</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" COLSPAN="3">Office for Technology Commercialization</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Date:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">May&nbsp;24, 2012</P></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">Date:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">May 11, 2012</P></TD></TR>
</TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P> 
 
</BODY></HTML>
</TEXT>
</DOCUMENT>
